ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Trading 08-21 11:47:18 EDT

0.9200

+0.0301

+3.38%

High0.9200	Low0.8800	Vol14.16K
Open0.9200	D1 Closing0.8899	Amplitude4.49%
Mkt Cap24.52M	Tradable Cap20.08M	Total Shares26.65M
T/O12.77K	T/O Rate0.06%	Tradable Shares21.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":0.92,"timestamp":1787327109947,"preClose":0.8899,"halted":0,"volume":14164,"delay":0,"changeRate":0.03382402517136759,"floatShares":21826200,"shares":26654365,"eps":-0.285468,"marketStatus":"Trading","change":0.0301,"latestTime":"08-21 11:47:18 EDT","open":0.92,"high":0.92,"low":0.88,"amount":12769.87246508,"amplitude":0.044949,"askPrice":0.9347,"askSize":100,"bidPrice":0.9101,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.285468,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787342400000},"marketStatusCode":2,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":0.8899,"preHourTrading":{"tag":"盘前","latestPrice":0.89,"preClose":0.8899,"latestTime":"09:28 EDT","volume":616,"amount":548.31118496,"timestamp":1787318915019,"change":0.0001,"changeRate":0.000112,"amplitude":0.020002},"postHourTrading":{"tag":"盘后","latestPrice":0.8899,"preClose":0.8899,"latestTime":"17:57 EDT","volume":28,"amount":24.9346,"timestamp":1787263027633,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.365989,"impliedVol":0.4964,"impliedVolPercentile":0.1116},"requestUrl":"/m/hq/s/ABVC/wiki","defaultTab":"wiki","newsList":[{"id":"2659815471","title":"Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2659815471","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659815471?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"contract development and manufacturing organization, to complete the. requested CMC work and advance process validation for CTx-1301, which. -- Product Distribution: On July 21, 2026, the Company signed an exclusive. services agreement with Prasco, LLC to establish the commercial. distribution infrastructure for the launch of CTx-1301, providing. designed to support broad national availability across maj","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2237443895.HKD","03160","IE00B1BXHZ80.USD","LU0267386448.USD","BK4588","LU0882574139.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","ADHD","BK4007","ABVC","LU2746668461.USD","BK4604","IE00BHPRN162.USD","LU2237443978.SGD","LU2065732104.USD","LU2237443622.USD","BK4555","LU2237443465.HKD","LU2746668974.SGD","LU0170899867.USD","TM","LU1363072403.SGD","BK4585","LU2237443382.USD","PRGS","IE00BFXG1179.USD","CMC","BK4006","LU0971096721.USD","LU2237443549.SGD","CING","BK4099","LU0149725797.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900693","title":"ABVC Biopharma FY26 Q2 Net Loss Narrows 65% to $810,481","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900693","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900693?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565671,"startTime":"0","endTime":"0","summary":"ABVC Biopharma FY26 Q2 net loss narrows 65% to $810,481ABVC Biopharma posted a Q2 net loss of $810,481, narrowing 65% from the year-earlier quarter.Operating loss tightened to $779,526 as operating ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL7mLjFj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909150","title":"ABVC BioPharma Delays BioKey (Cayman) Share Distribution to Aug. 21 from Aug. 3 in 8-K Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909150","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909150?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:06","pubTimestamp":1786550771,"startTime":"0","endTime":"0","summary":"ABVC BioPharma delays BioKey (Cayman) share distribution to Aug. 21 from Aug. 3 in 8-K amendmentABVC Biopharma amended its 8-K to delay the planned BioKey (Cayman) share distribution to Aug. 21, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbq9CXb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659920909","title":"ABVC Biopharma - Biokey (Cayman) Share Distribution Rescheduled for August 21, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659920909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659920909?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:04","pubTimestamp":1786550673,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN449156:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909927","title":"ABVC Biopharma - Postpones Biokey (Cayman) Share Distribution - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909927?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:04","pubTimestamp":1786550673,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN449156:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658150918","title":"Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2658150918","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658150918?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:30","pubTimestamp":1786451400,"startTime":"0","endTime":"0","summary":"Findings further validate Cingulate’s Precision Timed Release (PTR) platform and its trimodal drug delivery approachKANSAS CITY, Kan., Aug.  11, 2026  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342703/0/en/cingulate-publishes-peer-reviewed-data-demonstrating-ctx-1301-s-differentiated-pharmacokinetic-profile.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADHD","CING","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657165660","title":"Collegium Q2 2026 earnings: ADHD growth offsets pain portfolio pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2657165660","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657165660?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:54","pubTimestamp":1786067655,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical’s Q2 2026 net product revenue rose 6% to $199.9 million, while GAAP diluted EPS swung to a $0.46 loss from earnings of $0.34. Adjusted EBITDA increased 8% to $113.8 million as JORNAY PM revenue climbed 41% and AZSTARYS contributed $12.9 million for a partial quarter, offsetting a 9% decline in the pain portfolio. The company lowered full-year product revenue and adjusted EBITDA guidance because authorized-generic Nucynta pricing was weaker than expected, while raising its AZSTARYS revenue range.","market":"us","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262086846-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DECU","GXDW","VGFPF","VOTE","ABVC","RGLO","FEBU","PMDE","JOYT","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657507137","title":"Yukiguni Maitake Sees FY Net Y2.54b","url":"https://stock-news.laohu8.com/highlight/detail?id=2657507137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657507137?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:30","pubTimestamp":1785997800,"startTime":"0","endTime":"0","summary":"Yukiguni Maitake Co. Ltd. also released the following forecasts:. Results are based on IFRS accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657951555","title":"BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657951555","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657951555?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:39","pubTimestamp":1785890370,"startTime":"0","endTime":"0","summary":"BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-def","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ABVC","BB1.AU","BK7094","EPV","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302870","title":"NASDAQ Trade Halt Halt News Pending at 04:43 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302870","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302870?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:43","pubTimestamp":1785789839,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 04:43 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nAQN2MCX7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037500","title":"Press Release: Helus Pharma Appoints Michael Halstead as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037500","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656037500?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:40","pubTimestamp":1785757200,"startTime":"0","endTime":"0","summary":"Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & JohnsonExperienced executive with a proven track r","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4588","BK4585","BK4232","R","BK4555","BK4139","BK4099","ABVC","BK4022","TM","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656461013","title":"BlinkLab requests ASX trading halt ahead of material ADHD study results","url":"https://stock-news.laohu8.com/highlight/detail?id=2656461013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656461013?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:50","pubTimestamp":1785714616,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Blinklab Limited ( ($AU:BB1) ). BlinkLab Limited has requested and been granted a trading halt on its securitie...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blinklab-requests-asx-trading-halt-ahead-of-material-adhd-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blinklab-requests-asx-trading-halt-ahead-of-material-adhd-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADHD","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656278391","title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656278391","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656278391?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:00","pubTimestamp":1785531600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., July  31, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar TMS technology with direct patient care through","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3337067/0/en/Neuronetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","TMS","STIM","BK4082","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656395734","title":"Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2656395734","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656395734?lang=en_us&edition=fundamental","pubTime":"2026-08-01 02:55","pubTimestamp":1785524128,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on CTNM stock, giving a Buy rating today. Debanjana Chatterjee has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-on-contineum-therapeutics-with-unchanged-26-price-target-backed-by-advancing-ipf-and-mdd-pipelines-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-on-contineum-therapeutics-with-unchanged-26-price-target-backed-by-advancing-ipf-and-mdd-pipelines-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655376838","title":"ABVC Biopharma Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655376838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655376838?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:32","pubTimestamp":1785270745,"startTime":"0","endTime":"0","summary":"ABVC Biopharma announces special shareholder meetingABVC Biopharma will hold a virtual special shareholder meeting on Sept. 18, 2026 via Zoom.Vote planned on adopting a 2026 Equity Incentive Plan to r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLc5qyd0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027540","title":"Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654027540?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:32","pubTimestamp":1785241920,"startTime":"0","endTime":"0","summary":"New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care deliveryMALVERN, Pa., July  28, 2026  (GLOBE NEW","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334270/0/en/Greenbrook-Opens-National-Center-of-Excellence-for-Advanced-Interventional-Psychiatry-in-Rockville-Maryland.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","STIM","AEIS","TMS","ABVC","NHLD","LU0757428866.USD","BK4157","LU1815336091.USD","BK4082","IE00B66KJ199.SGD","IE0031619046.USD","BK4139","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172775791","title":"US FDA Approves Otsuka's Novel ADHD Drug Simtriyo for Market Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1172775791","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172775791?lang=en_us&edition=fundamental","pubTime":"2026-07-28 15:23","pubTimestamp":1785223420,"startTime":"0","endTime":"0","summary":"On July 27, the U.S. Food and Drug Administration (FDA) officially approved the once-daily extended-release capsule Simtriyo (centanafadine), developed by Japan's Otsuka Pharmaceutical, for the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK4588","ABVC","BK4139","LNGR","ADHD","MEDX","LABU","IBBQ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653251786","title":"Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003","url":"https://stock-news.laohu8.com/highlight/detail?id=2653251786","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653251786?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:51","pubTimestamp":1784670675,"startTime":"0","endTime":"0","summary":"An update from Helus Pharma ( ($HELP) ) is now available. Helus Pharma said on July 21, 2026 that it has completed enrollment ahead of schedule in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/helus-pharma-fast-tracks-phase-3-enrollment-for-mdd-drug-hlp003?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/helus-pharma-fast-tracks-phase-3-enrollment-for-mdd-drug-hlp003?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651910760","title":"Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651910760","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651910760?lang=en_us&edition=fundamental","pubTime":"2026-07-14 22:26","pubTimestamp":1784039193,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 with ADHD, measuring change in ADHD-RS-5 total score over 6 weeks.\nThis pediatric Phase 3 start, alongside an ongoing adolescent Phase 3 program, underscores Axsome’s push to broaden solriamfetol’s role across multiple CNS indications and age groups.\nWe’ll now examine how advancing solriamfetol...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTH","BK4135","BK4585","AXSM","BK4007","CNS","BK4505","BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105725","title":"Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105725?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:30","pubTimestamp":1784032200,"startTime":"0","endTime":"0","summary":"Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT2C) pharmacodynamics approved in its FDA product labeling.Qe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326843/19871/en/Supernus-Celebrates-Five-Year-Anniversary-of-Qelbree-FDA-Approval-Continuing-to-Deliver-on-Real-World-Experience-in-ADHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","ABVC","BK4135","PPD","LU1169589451.USD","ADHD","BK4588","BK4561","BK4139","BK4023","BK4121","BK4585","LABU","PD","LU1169590202.USD","CDC","CNS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.0724},{"period":"1month","weight":-0.2765},{"period":"3month","weight":-0.2194},{"period":"6month","weight":-0.4107},{"period":"1year","weight":-0.712},{"period":"ytd","weight":-0.5822}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.375,"avgChangeRate":1.167092},{"month":7,"riseRate":0.375,"avgChangeRate":-0.130229},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.061646},{"month":9,"riseRate":0.375,"avgChangeRate":-0.065685},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction